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Glioblastomas are the most lethal primary brain tumor that frequently relapse or progress
as focal masses after radiation, suggesting that a fraction of tumor cells are responsi-
ble for the tumor regrowth. The identification of a brain tumor cell subpopulation with
potent tumorigenic activity supports the cancer stem cell hypothesis in solid tumors. The
goal of this study is to determine a methodology for the establishment of primary human
glioblastoma cell lines. Our aim is achieved by taking the following approaches: (i) the
establishment of primary glioblastoma cell culture; (ii) isolation of neurospheres derived
from glioblastoma primary cultures; (iii) selection of CD133 cells from neurospheres, (iv)
formation of subspheres in the CD133-positive population, (v) study of the expression
level of GFAP, CD133, Nestin, Nanog, CD34, Sox2, CD44, and CD90 markers on tumor
subspheres. Hence, we described a successful method for isolation of CD133-positive
cell population and establishment of glioblastoma neurospheres from this primary cul-
ture, which are more robust than the ones derived straight from the tumor. Pointed out
that the neurospheres derived from glioblastoma primary culture showed 29% more cells
expressing CD133 then the ones straight tumor-derived, denoting a higher concentration
of CD133-positive cells in the neurospheres derived from glioblastoma primary culture.
These CD133-positive fractions were able to further generate subspheres.The subspheres
derived from glioblastoma primary culture presented a well-defined morphology while the
ones derived from the fresh tumor were sparce and less robust. And the negative fraction of
CD133 cells was unable to generate subspheres. The tumor subspheres expressed GFAP,
CD133, Nestin, Nanog, CD44, and CD90. Also, the present study describes an optimiza-
tion of neurospheres/subspheres isolation from glioblastoma primary culture by selection
of CD133-positive adherent stem cell.
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INTRODUCTION
Nervous system (NS) tumors are classified into seven categories
that include primary tumors, according to World Health Orga-
nization (WHO) (neuroepithelial tissues, meninges, cranial and
paraspinal nerves, germ cell and sellar region tumors, lymphoma,
and hematopoietic neoplasms), besides secondary or metastatic
tumors.
Central Brain Tumor Registry of the United States of Amer-
ica (CBTRUS 2008/2011) data shows that 64,530 new cases
of primary NS tumors were diagnosed in 2010, which repre-
sents 1.44% of all malign neoplasms diagnosed in the USA.
In spite of the low incidence, the primary NS tumors are
highly lethal and accounted for 13,140 deaths in USA during
2010.
Usually, central NS tumors are classified as gliomas and non-
gliomas. There are several different types of gliomas, which are
determined by the glial cell that give rise to the tumor. Astro-
cytoma, oligodendroglioma, glioblastoma, oligoastrocytoma, and
ependymoma are examples of gliomas. Gliomas are 31% of the pri-
mary tumors and 80% of the NS malignant tumors. Glioblastoma,
which is a subset of glioma (GBM, WHO astrocytoma grade IV)
is the most frequent and malignant brain tumor. Although many
advances have been made in these tumors diagnosis, glioblastoma
generally has a very poor prognosis (1, 2).
Glioblastoma treatment is difficult due to some tumor features
such as: (i) extensive tumor infiltration in the surrounding healthy
brain tissue; (ii) tumor mass formed by distinct cell types with
multiple cell markers; (iii) resistance to chemo and radiotherapy
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(3). These characteristics have driven investigators to hypothesize
that glioblastoma is a heterogeneous combination of cells and can-
cer stem cells. Cancer stem cells are defined as a small fraction of
tumor-initiating cells which have a high tumorigenic potential and
proliferation rate (3, 4).
The CD133 has been used as a marker to identify regular neural
stem cells (5), and also tumor neural stem cells. However there
are three items used to confirm if the CD133 isolated cells are
tumor stem cells instead regular ones: (1) generation of clono-
genic cells (neurospheres); (2) proliferative and self-renew ability;
(3) capacity of behaving as tumor initiators when implanted in
immunodeficient mice.
Quantitative analysis of CD133-positive cells has generally
found them to be present at low levels in human gliomas, glioma
neurosphere, and established glioma cell lines (6), consistent with
the assumption that tumor stem cells are a rare cell population
in solid tumors. However, some studies reported an exception-
ally high CD133 (20–60%) fraction in some human glioblastoma
and/or glioma cell lines (7), and other authors also have reported
that glioblastoma contain more than 25% of CD133-positive
cells (8).
Facchino and coworkers (9) described that tumor brain puri-
fied CD133 cells are able to generate neurospheres in culture and
also differentiate into glial cells and neurons in presence of induc-
tors. The glioblastoma CD133-positive cells can generate highly
invasive tumors in vivo (10–12), that are chemo resistant, radio
resistant and therefore responsible for tumor progression and
relapse after conventional therapy (2, 13).
The true role of CD133 in the initiation and progression of
brain tumors is still an unclear process. Even though there are sev-
eral articles that refers CD133 as the main tumor stem cell marker,
still exists some differences among published articles regarding
standardization methods. For example, there are several studies
that have isolated stem cells from primary glioblastoma, using
CD133 magnetic microbeads and obtained neurospheres by the
use of supplements such as N2, B27, EGF, FGF with variable results
(3, 12, 14). On the other hand, there is a group that isolated reg-
ular neural stem cell from a health volunteer using an adherent
cells protocol with very good results (15). Thus, is highly desirable
to establish standard methods for isolation, culture, and cellular
characterization of neurospheres and subspheres aiming future
studies of these cells tumorigenicity.
In the present study, we developed a modified procedure for
neurospheres and subspheres isolation from human glioblastoma
primary culture.
MATERIALS AND METHODS
In this study, we analyzed five samples of glioblastoma obtained
from patients submitted to brain tumor surgery removal pro-
cedures in the Neuro-Oncology Center of the Hospital Israelita
Albert Einstein (HIAE). All patients signed an informed con-
sent for the study (Ethical Committee of the HIAE approved by
number 687).
The brain tumors diagnoses were performed by the Integrated
Neuro-oncology program team from HIAE based on MRI data and
histopathology analysis (16). The histopathology data classified all
tumors as GFAP positive, categorizing them as grade IV.
ESTABLISHMENT OF PRIMARY CELL CULTURE OF HUMAN
GLIOBLASTOMA SAMPLES
Fresh glioblastoma samples were washed and minced in PBS
(1×) followed by enzymatic dissociation with collagenase-I
0.3% (Sigma-Aldrich). The isolated cells were resuspended in
Dulbecco’s Modified Eagle’s Medium-Low Glucose (DMEM-
LG, GIBCO Invitrogen) supplemented with l-Glutamine
200 mM, Antibiotic–Antimycotic (10,000 U/mL sodium peni-
cillin, 10,000µg/mL streptomycin sulfate, and 25µg/mL ampho-
tericin B – GIBCO/Invitrogen Corporation), and 10% Fetal Bovine
Serum (GIBCO/Invitrogen Corporation). Next, the cells were
seeded in 25 cm2 cultures flasks and maintained at 37°C, 5% CO2.
The culture medium was changed every other day.
GLIOBLASTOMA NEUROSPHERES CULTURE DERIVED FROM TUMOR
PRIMARY CULTURE
The cells obtained in the primary culture described above were
resuspended in tumor brain stem cells medium which is Dulbecco’s
Modified Eagle Medium/F12 (Gibco), supplemented with N2
(Gibco), EGF (20 ng/mL, Invitrogen), bFGF (20 ng/mL, Gibco),
leukemia inhibitory factor 10 ng/µL (LIF; Chemicon), and B27
(1:50; Life Technologies). Viable cells were seeded in 24-well plates
at 2× 104 density. The cells were maintained in a humidified
incubator (Thermo Fisher Scientific Inc. 3110, Waltham, MA,
USA) with 5% CO2 at 37°C and culture medium were changed
every 3 days.
GLIOBLASTOMA NEUROSPHERES CULTURE DERIVED FROM FRESH
TUMOR
Fresh glioblastoma samples were washed and minced in PBS
(1×) followed by enzymatic dissociation using collagenase-I 0.3%
(Sigma-Aldrich). Cells were resuspended in tumor brain stem cells
medium. Viable cells were seeded in 48-well plates at 1× 102 den-
sity. The cells were maintained in a humidified incubator (Thermo
Fisher Scientific Inc. 3110, Waltham, MA, USA) with 5% CO2 at
37°C and culture medium were changed every 3 days (17).
IMMUNOCYTOCHEMICAL STAINING OF CD133 CELLS GLIOBLASTOMA
Glioblastoma tumor samples were washed with 1% PBS and
tumor cells were disaggregated in 1% PBS solution containing
0.3% collagenase-I. Cells derived from the tumor were then resus-
pended in supplemented Dulbecco’s Modified Eagle’s Medium
(DMEM-Low Glucose) and plated at a density of 3× 106 live
cells/60 mm plate. Next, cells were fixed with 4% paraformalde-
hyde and stained with antibody against human CD133/1 (human
monoclonal IgG1; 1:1000 dilution; Miltenyi Biotec). After wash-
ing the cells, they were incubated with KIT Advanced ™ HRP
Dako (K4067) Advanced ™ HRP Enzyme and followed by the
application of the substrate-chromogen solution (DAB+).
PURIFICATION OF BRAIN TUMOR STEM CELLS USING CD133
MICROBEADS
The neurospheres colonies were dissociated using StemPro Accu-
tase (Invitrogen) and maintained at room temperature for 10 min.
The cells were labeled with CD133 magnetic microbeads (MACS –
Miltenyi Biotech) and selected by affinity column according man-
ufactory instructions (Miltonic Biotech). In order to verify the
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FIGURE 1 | Establishment of primary cell culture of human
glioblastoma samples: immunocytochemical staining and
transmission electron microscopy (TEM) of CD133+ cells glioblastoma.
(A) Analysis of primary culture of glioblastoma. (B,C) Immunolocalization of
CD133+ cells by immunocytochemical staining. (E) Immunolocalization of
CD133+ cells immunofluorescence assays (G,H) Immunolocalization of
CD133+ cells by transmission electron microscopy and that arrows indicate
electron-dense nanoparticles in the glioblastoma cell surface recognizing
the CD133 epitope. (D,F) Glioblastoma cells from control group of
immunocytochemical and immunofluorescence techniques, respectively.
Representative figure of five samples of glioblastoma. (A) Magnification
400×. (B–F) Magnification 600×. Scale bars: (G,H) 0.25µm.
cells populations separation efficiency, the CD133+ fraction was
stained with CD133/2PE and evaluated by flow cytometry FAC-
SARIA (BD Biosciences, San Jose, CA, USA) and FACSDIVA
software (BD Biosciences, San Jose, CA, USA) (18).
TRANSMISSION ELECTRON MICROSCOPY OF GLIOBLASTOMA CD133+
CELLS
After purification process an aliquot of CD133-positive cells
fraction was also analyzed by Transmission electron microscopy
(TEM) (18). The cells were fixed in 1% glutaraldehyde and 0.2 M
FIGURE 2 | Isolation of tumor neurospheres derived from
glioblastoma primary culture and derived straight from the tumor.
(A,C,E,G) Glioblastoma neurospheres culture derived from fresh tumor.
(B,D,F,H) Glioblastoma neurospheres culture derived from tumor primary
culture. Representative figure of five samples of glioblastoma. (A,B)
Magnification: 100×, (C) magnification: 200×, (D–H) magnification: 600×.
cacodylate buffer for 2 h at 4°C. Cells were washed in cacodylate
buffer, 2 times for 15 min each. Post-fixation was performed in 1%
osmium tetroxide for 1 h at 4°C, followed by another two washes
in the same buffer. For contrast, the pellet was immersed in a
solution of uranyl acetate in acetone for 30 min. After dehydra-
tion, the material was embedded in Epon resin diluted in acetone
(1:1) and incubated at 4°C with agitation for 24 h. The pellet was
then transferred to pure Epon resin and incubated at 60°C for
72 h, until completely polymerized. Semi and ultrathin sections
were obtained through Porter Blum ultramicrotome. The semithin
sections were stained with azur II (1%) and methylene blue (1%).
The ultrathin sections were placed on copper grids and stained
with uranyl acetate and lead citrate. The grids were studied and
photographed under a TEM (PHILIPS CM100).
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FIGURE 3 | Purification of brain tumor stem cells using CD133
microbeads followed preparation of tumor subspheres.
Immunophenotypic characterization by flow cytometry tests, evaluating the
efficiency of magnetic separation of cell fractions positive for the antigenic
marker CD133 in neurosphere derived from glioblastoma primary
culture – 89.0% (A) and derived from fresh tumor – 60.0% (B). CD133+ cells
in neurospheres derived from glioblastoma primary culture were able to
further generate subspheres. Culture of glioblastoma subspheres, compared
with the absence of subspheres obtained from CD133− fractions (C). Graphic
representation of neurospheres formation per culture type, such as tumor
primary culture CD133+ and fresh tumor CD133+. Representative figure of
five samples of glioblastoma. Magnification: 600×.
PREPARATION OF TUMOR SUBSPHERES
CD133+ selected and CD133− depleted cells populations, derived
from column affinity purification, were resuspended in tumor
brain stem cells medium and seeded in 24-well plates at 1× 103
density. Formation of subspheres was only observed in CD133-
positive cells and documented by phase-contrast microscopy
(Olympus IX51).
IMMUNOPHENOTYPING OF TUMOR SUBSPHERES BY FLOW
CYTOMETRY
We analyzed cell-surface expression of specific markers in sub-
spheres cells. We used monoclonal antibodies commercially
available and followed the manufacturer’s instructions. Briefly,
subspheres were harvested by treatment with StemPro Accu-
tase Cell Dissociation Reagent (GIBCO-Invitrogen, Carlsbad, CA,
USA), washed with PBS (pH= 7.4). Next the cells were stained
with the selected monoclonal antibodies, and incubated in the
dark for 30 min at room temperature. For intracellular staining
the cells were first fixed (Facs lysing solution, BD) and perme-
abilized (permeabilization solution 2, BD Biosciences, San Jose,
CA, USA). The following human antibodies were used: GFAP
PE (clone: 51-10C9; BD Pharmingen, San Diego, CA, USA),
Nestin APC (clone: AD2; BD Pharmingen, San Diego, CA, USA),
CD133-PE (clone: 133/2; Miltenyi biotec, Bergisch Gladbach,
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FIGURE 4 | Immunophenotyping of tumor subpheres by flow cytometry.
Immunophenotypic characterization by flow cytometry assays showing the
pattern of expression of markers GFAP (88.2%), CD133 (56.5%), Nestin
(64.2%), Sox2 (17.7%), CD34 (34.0%), and Nanog (15.5%) in glioblastoma
subsphere samples and the co-expression of CD133 with GFAP (52.5%) and
Nestin (44.8%). Representative figure of five samples of glioblastoma.
Germany), Sox2 PerCP-Cy5.5 (clone: 245610; R&D System), CD34
PE (clone: 581; BD Pharmingen, San Diego, CA, USA), Nanog
PE (clone: 781; BD Pharmingen, San Diego, CA, USA), CD44
PerCP-Cy5.5 (clone: IM7; BD Pharmingen, San Diego, CA, USA),
CD90 APC (clone: 5E10; BD Pharmingen, San Diego, CA, USA),
and the related isotype controls. The data acquisition was done
by FACSARIA flow cytometer (BD Biosciences, San Jose, CA,
USA) and analyzed by FACSDIVA software (BD Biosciences,
San Jose, CA, USA) or Flow Jo Software (TreeStar, Ashland,
OR, USA).
IMMUNOFLUORESCENCE ASSAY
To the immunofluorescence assays, the subspheres were fixed with
formaldehyde 4%, permeabilized with 0.1% Triton X-100. The
samples were incubated with the following fluorescently labeled
antibodies: GFAP-FITC (1:100; Santa Cruz), CD133-PE (1:100;
Miltenyi biotec, Bergisch Gladbach, Germany), Nestin-PE (1:200;
BD Bioscience), and Nanog FITC (1:400; R&D System). The cells
were also stained with 4′, 6′-diamidino-2 phenylindole (DAPI;
Sigma). These cells were analyzed by fluorescence microscopy
(Olympus IX51).
RESULTS
ESTABLISHMENT OF PRIMARY CELL CULTURE FROM HUMAN
GLIOBLASTOMA SAMPLES SHOWS THE PRESENCE OF CD133-POSITIVE
CELLS
Primary cell cultures were obtained from glioblastoma samples.
These cells were homogenous, presented fusiform format, and
were arranged in multidirectional bundles in culture (Figure 1A).
Immunocytochemical (Figures 1B,C) and immunofluorescence
(Figure 1E) assays revealed the CD133 expression in glioblastoma
primary cultures. The Figures 1D and 1F represented glioblastoma
cells from control group of immunocytochemical and immunoflu-
orescence techniques, respectively. Ultrastructural analysis using
electron microscopy highlighted the presence of electron-dense
granules in the glioblastoma cell surface. These granules are
compatible with the presence of anti-human CD133 microbeads
attached to the cell membrane (Figures 1G,H).
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GLIOBLASTOMA PRIMARY CULTURES GENERATE NEUROSPHERES
WITH SUPERIOR PHENOTYPE THAN THOSE ISOLATED FROM FRESH
TUMOR
After the glioblastoma digestion the cells were resuspended in
tumor brain stem cells medium and in culture generated neu-
rospheres. However the cells derived from glioblastoma primary
culture generated neurospheres with more developed and robust
morphology (Figures 2B,D,F,H) compared with those isolated
straight from the fresh tumor (Figures 2A,C,E,G).
CD133 MICROBEADS PURIFIED NEUROSPHERES ARE ABLE TO
GENERATED TUMOR SUBSPHERES
The glioblastoma neurospheres were treated with StemPro Accu-
tase and selected by CD133+ affinity column. The neurospheres
were evaluated for CD133 purity, and the glioblastoma primary
culture derived neurospheres were 89% purity (Figure 3A) while
the tumor fresh isolated neurospheres presented only 60% purity
(Figure 3B). These results show a higher concentration of CD133-
positive cells in neurospheres derived from glioblastoma primary
culture. These CD133-positive fractions were able to further gen-
erate subspheres. The subspheres derived from glioblastoma pri-
mary culture presented a well-defined morphology while the ones
derived from the fresh tumor were diffuse and less robust. Also,
CD133-positive cells derived from glioblastoma primary culture
were able to generate 75% more subspheres than the ones derived
from the fresh tumor (Figure 3C). The negative fraction of CD133
cells were unable to generate subspheres (Figures 3A,B).
IMMUNOPHENOTYPING OF TUMOR SUBSPHERES BY FLOW
CYTOMETRY AND FLUORESCENCE MICROSCOPY
The tumor subspheres were analyzed by flow cytometry (Figures 4
and 5) and fluorescence microscopy (Figure 6). The flow cytom-
etry analyses showed 92.1% cells expressing GFAP, a tumor glial
marker, of which 52.5% double stained for CD133 and 71% cells
expressing Nestin, an immature neural stem cell marker, of which
44.8% double stained for CD133. Also, a percentage of these
cells also co-expressed Nanog (15.5%) and Sox2 (17.7%), stem
cells transcription factors related to pluripotency and self-renewal
potential. In addition, the CD133-positive cells also expressed
CD44 (94.0%), CD90 (94.4%), and CD34 (34%). CD44 it is
described as a homing molecule to lymph node and was previ-
ously related with cells metastatic potential, CD90 and CD34 are
considered stem cell markers (Figures 4 and 5).
These results corroborate with subsphere immunofluorescence
assays showing the same expression pattern of the immunophe-
notypic markers. We found that most GFAP positive cells
(Figures 6B,F) co-expressed CD133 (Figure 6C) and Nestin
(Figure 6G), as can be seen by overlap in Figures 6D,H. Double
staining also revealed that most Nestin-positive cells (Figure 6J)
co-expressed Nanog (Figure 6I).
FIGURE 5 | Immunophenotyping of tumor subspheres by flow
cytometry. The immunophenotypic profile of CD133+ cells showed that
these cells also expressed high levels of markers CD44 (94.0%) and CD90
(94.4%). Histogram: cells expressing high levels of markers CD44, CD90, and
CD133. Dot plots: isotype control gated cells in the first column, and in the
second column double staining of CD133/CD44 and CD133/CD90.
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FIGURE 6 | Immunofluorescence assays of glioblastoma subspheres
demonstrate the expression pattern of immunophenotypic markers:
(A) DAPI, (B) GFAP, (C) CD133, (D) overlay (A–C); (E) DAPI, (F) GFAP,
(G,J) Nestin, (H) overlay, (I) Nanog. Representative figure of five samples
of glioblastoma. (A–I) Magnification: 600×.
DISCUSSION
Despite advances in therapeutics, the molecular and cellular mech-
anisms that initiate and establish human brain cancer have not
been completely elucidated. Recent studies have showed that brain
cancer evolved from a specific tumorigenic cell subset with highly
self-renew potential called tumor or cancer stem cell (19, 20).
Even though, there isn’t a consensus about the true nature of
these cancer stem cells. The cancer stem cell hypothesis is based
on the observation that brain tumors are a heterogeneous cell
mass that comprise a rare cell population identified by CD133
expression. The CD133-positive cells are able to initiate a new
tumor formation and they are responsible for metastasis in vivo or
neurospheres formation in vitro (3).
In order to verify the cancer stem cell hypothesis, it is
first necessary to establish preeminent protocols for cells isola-
tion/purification, better cell culture conditions, and procedures
for this cell population characterization.
Current protocols in stem cell biology describe a procedure for
neurospheres isolation from fresh tumor (3, 17, 19, 21, 22). In
addition, our study describes an optimization of CD133-positive
cells isolation and the establishment of neurospheres/subspheres
from glioblastoma primary culture.
Immunocytochemical and immunofluorescence assays showed
CD133-positive cells presence in glioblastoma primary cell culture.
Under the electron microscopy, ultrastructural analysis showed the
microbead anti-CD133 attached to the selected cells.
The CD133 selected cells were able to further, in cell culture
conditions, generate tumor neurospheres/subspheres as a clono-
genic set of cells. Our study confirmed the ability of CD133
microbeads to enrich cells with stem-like properties. This finding
is important when considering cells heterogeneity in the tumoral
mass (23).
CD133-positive cells presence in brain tumor are accepted,
even with restriction, as a presence of brain cancer stem cells,
which contribute to tumor initiation and recurrence. Further-
more, CD133 expression in brain tumors has been identified as
a poor prognosis factor and as critical drivers of tumoral progres-
sion, due to their self-renewal capacity and limitless proliferative
potential (24–27). A recent study, showed that CD133-positive
glioma cells have a molecular profile similar to embryonic stem
cells, and CD133-positive glioma cells are more tumorigenic than
the CD133 negative population isolated from the same tumor
(28). Others, also suggested that CD133 expression could be
used as an indicator of brain tumors aggressiveness and dis-
semination potential, as well as a target for new therapies in
glioblastoma (19, 27–29).
There is an overall lack of consensus concerning methodolo-
gies for cell sorting and stemness verification. Moreover, there is
a highly relevant debate about the best method for culturing the
human glioblastoma stem cells: some groups proposed the use
of adherent monolayer cultures rather than non-adherent cul-
tures, since a homogeneous exposure to growth factors, oxygen
and nutrients increases the possibility of obtaining a more homo-
geneous cell population (15, 30). A study by Motegi et al. suggested
that CD133-positive cells can be efficiently isolated from U87MG
adherent cultures, which is a malignant glioma cell line (31).
We have modified the CD133 cell population isolation method
and neurospheres/subspheres establishment in this study. The
glioblastoma primary culture derived neurospheres with 29%
more CD133-positive cells when compared to tumor fresh isolated
neurospheres. These CD133-positive fractions were able to further
generate subspheres. The subspheres derived from glioblastoma
primary culture presented a well-defined morphology while the
ones derived from the fresh tumor were sparce and less robust.
Also, CD133-positive cells derived from glioblastoma primary cul-
ture were able to generate 75% more subspheres than the ones
derived from the fresh tumor. The negative fraction of CD133
cells was unable to generate subspheres.
Considering these findings, we can suggest that the tumor
mass, which has distinct cell types with distinct expressions,
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FIGURE 7 | Summary of protocol parameters for isolation, culture,
and immunophenotypic characterization of glioblastoma (GBM)
neurospheres derived from tumor primary culture. This study showed
that the method is effective for: (i) the establishment of primary
glioblastoma cell culture; (ii) study immunocytochemical and
ultrastructural staining of CD133 cells glioblastoma: (iii) culture and
isolation of tumor neurospheres derived of primary culture; (iv)
purification of the cell population known for initiate the tumor (CD133+
cell) by MACS and evaluation by flow cytometry; (v) purification of stem
cells using CD133 microbeads by; (vi) formation of subspheres in
CD133+ cells in neurospheres derived from glioblastoma primary culture;
(vii) study of the expression level of GFAP, CD133, Nestin, Nanog, CD34,
and Sox2 markers on tumor subspheres by flow cytometry and
immunofluorescence assay.
comprises adherent and no adherent cells. In our study, we
derived neurospheres from glioblastoma primary cultures adher-
ent CD133-positive cells, which the expression was detected by
immunocytochemical and immunofluorescence assays. Our find-
ings corroborate another study that attributes to an adherent cell
the source of CD133 in glioblastoma (32).
Glioblastoma subpheres analysis revealed that most CD133 iso-
lated cells co-expressed GFAP and Nestin, relating the isolated cells
with neural and stem cell origin. GFAP expression reveals glial
origin and Nestin characterizes commitment to neural immature
lineages (13). Tumor subsphere immunofluorescence assays also
revealed that most Nestin-positive cells co-expressed Nanog, lead-
ing us to believe that the subspheres also contains undifferentiated
neural stem cell (33).
Recently, CD90 another stem cell marker, has been identified
as a prognostic marker for high-grade gliomas and CD44 as a
metastatic potential marker (34, 35). In addition, CD133, CD90,
CD44, and Nestin co-expression may explain the tumorigenic
potential of these cells, since Nestin and CD44 are also known as
regulators of migration, invasion and tumor growth. Thus, CD133
expression in combination with Nestin, CD44, and CD90, may
lead us to a cell profile with highly tumorigenic potential. Con-
sequently, these markers may be useful as a target for molecular
therapy in gliomas, including glioblastoma (34–37).
During this study we were able to describe a novel methodol-
ogy for neurospheres isolation from glioblastoma primary culture
through CD133 adherent cells isolation (Figure 7). We were able
to generate subspheres from the CD133 isolated cells, which were
characterized by its co-expression with GFAP, Nestin, Nanog,
CD44, and CD90 establishing the initial and successful method
for further studies with these cell populations. These protocols
may help further studies about the gliomagenesis process by
pinpointing the cell type that is responsible for tumor origin.
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